A61K 2239/11
Antigen recognition domain
A61K2239/11 (Antigen recognition domain) appears on 125 US grants and 891 published applications in this corpus.
Search patents in A61K- Granted patents
- 125
- Published applications
- 891
- Assignees
- 441
- Inventors
- 2,426
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 8 |
| 2017 | 0 | 8 |
| 2018 | 4 | 12 |
| 2019 | 5 | 16 |
| 2020 | 8 | 13 |
| 2021 | 7 | 23 |
| 2022 | 7 | 42 |
| 2023 | 11 | 74 |
| 2024 | 17 | 270 |
| 2025 | 32 | 258 |
| 2026 | 31 | 162 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Humanized CD19 antibody and use thereof15 Sep 2026US 12,735,482 B2Gracell Bioscience (Shanghai) Co., Ltd.
- Anti-CD20 antibodies and CAR-T structures18 Aug 2026US 12,709,644 B2TeneoBio, Inc.
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:011 Oct 2026US 2026/0297157 A1Board of Regents, The University of Texas System
- T-cell receptors targeting her2 and methods of use thereof1 Oct 2026US 2026/0297158 A1Board of Regents, The University of Texas System
- Car-t cell targeting cll1, preparation method therefor and use thereof1 Oct 2026US 2026/0297519 A1Carbiogene Therapeutics Co., Ltd.
Most cited
By later US patents
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Chimeric immunoreceptor useful in treating human cancers68US 8,497,118 B2City of Hope · 2013
- Chimeric antigen receptors targeting CD-1920US 10,287,350 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2019
- Cell19US 10,172,885 B2UCL Business PLC · 2019
- Cell13US 10,172,886 B2UCL Business PLC · 2019